Needham & Company Maintains a 'Hold' on Forest Labs (FRX); FDA Overwhelmingly Backs Approval of Aclidinium
Tweet
Share
E-mailGet Alerts FRX Hot Sheet
Price: $12.00 --0%
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Forest Laboratories (NYSE: FRX).
Analyst, Elliot Wilbur, said, "The FDA’s Pulmonary-Allergy Drugs Advisory Committee (AdCom) convened on Thursday (2/23/2012) to review the efficacy/safety of aclidinium (proposed brand name: Tudorza Pressair) as a treatment for COPD. Given the benign background documents released prior to the meeting, it was no surprise that the AdCom voted overwhelmingly (12-2) in support of FDA approval for aclidinium in its proposed indication."
"Aclidinium successfully met its primary endpoint (improvement in baseline FEV1) in three pivotal studies (COPD I, COPD II and ATTAIN) at weeks 12 and 24. The magnitude of FEV1 improvement with aclidinium 400 mg BID ranged from 72 mL to 124 mL across the three trials. The AdCom voted 12-0 in support of aclidinum’s efficacy in treating COPD. Some committee members expressed support for the strong bronchodilatory effect of aclidinium but believed other efficacy endpoints such as exacerbations were favorable but not compelling."
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $32.21 yesterday.
Analyst, Elliot Wilbur, said, "The FDA’s Pulmonary-Allergy Drugs Advisory Committee (AdCom) convened on Thursday (2/23/2012) to review the efficacy/safety of aclidinium (proposed brand name: Tudorza Pressair) as a treatment for COPD. Given the benign background documents released prior to the meeting, it was no surprise that the AdCom voted overwhelmingly (12-2) in support of FDA approval for aclidinium in its proposed indication."
"Aclidinium successfully met its primary endpoint (improvement in baseline FEV1) in three pivotal studies (COPD I, COPD II and ATTAIN) at weeks 12 and 24. The magnitude of FEV1 improvement with aclidinium 400 mg BID ranged from 72 mL to 124 mL across the three trials. The AdCom voted 12-0 in support of aclidinum’s efficacy in treating COPD. Some committee members expressed support for the strong bronchodilatory effect of aclidinium but believed other efficacy endpoints such as exacerbations were favorable but not compelling."
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $32.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Celcuity Inc (CELC) PT Lowered to $140 at Needham
- NANO Nuclear Announces Participation in Several Investor Conferences
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
